Effect of a DPP-4 inhibitor on left ventricular diastolic dysfunction in patients with type 2 diabetes and diabetic cardiomyopathy
- Conditions
- Type 2 diabetic patients with left ventricular diastolic dysfunction
- Registration Number
- JPRN-UMIN000003784
- Lead Sponsor
- Cardiovascular Dysfunction Study group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 120
Not provided
1,The patient under insulin treatment 2,The patient under alpha-GI or Gulinide treatment 3,Severe ketosis, diabetic coma, or precoma within the past six months 4,Severe infectious disease, pre/ post operation or serious injury 5,Type 1 diabetes mellitus 6,Insufficiently controlled diabetes mellitus (HbA1c >= 9.0% ) 7,Insufficiently controlled hypertension (SBP>=160mmHg) 8,Myocardial infarction or stroke within 6 months before recruiting 9,LV hypertrophy (LV wall thickness > 13mm) 10,The patient with atrial fibrillation 11,The patient with significant valvular disease 12,Women who are pregnant, possibly pregnant, or are breastfeeding 13,Mild renal dysfunction (sCr>=1.5 mg/dl) 14,Hypersensitivity or allergy to sitagliptin and voglibose 15, Patients who are determined by the investigators to be unsuitable
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change in e' and e'/E after 24 weeks
- Secondary Outcome Measures
Name Time Method